Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa Trial of MK-0941 Added to Basal Insulin in Type 2 Diabetes Mellitus
2008-006215-20Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing MK-0941 + basal insulin with Placebo + basal insulin (2 arms). Primary endpoints: Change from baseline in A1C at Week 20 and Safety and tolerability of MK-0941. Started Nov 2008; status: completed.
02
Drugs
mk-0941
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2008-006215-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006215-20.